Subgroup analysis demonstrated that the number and the percentages of patients with higher level of NT-proBNP in the CR group significantly decreased (p < 0.05), suggesting that phase 1 CR plus medication can further lower the levels of NT-proBNP in patients with CHD and AHF, which implies that phase 1 CR may improve the outcome in patients with HF. The gene discussed is NPPB; the disease is coronary artery disorder.